AGRAZINC 100 Commercial trial of AGRAZINC 100 IN PIGLETS VRS. STANDARD MINERAL ZNO CARRIED OUT IN BRASIL

AGRAZINC 100 TECHNICAL PERONNEL This project was conducted by Dr. Julio Maria Ribeiro Pupa, Technical and Scientfic consultant for ALL NUTRI LTDA, jointly with the personnel of the commercial farm and the farm´s general manager.

Bivalent cation minerals and the mucus on intestinal surface TITLE- Use microencapsulated zinc oxide , AGHRAZINC 100 in weaned piglets after 49 days. OBJECTIVE – Determine the of piglets during a period of 28 days after weaning , after applying two different dosages of microencapsulated zinc , AGRAZINC 100 compared to standard mineral zinc oxide , plus piglets rations.

METHODOLOGY The experiment was conducted in a commercial farm with normal challenges for the piglets. 252 piglets were used coming from mothers which were normally equalized and to which piglets colostrum was was administered normally . Normal maternity was followed to stimulate consumption of

AGRAZINC 100 And 0.2% During the 2 following weeks.The drinking water was supplied at will. The parameters analyzed were weight gain, feed consumption. Feed conversion, mortality , diarreah and morbidirty. The data collected were subjected to statistical analysis and medias compared to Tukey with a level of plus or minus 5%.

E. coli and GIT dysfunction RESULTS AND DISCUSSIONS- The results found were tabulated on table in tables 2 and 3. There was no significant differences (P less than 0.5) between the two treatments from the variations in weight at 21 days(P21), weight at 31 days(P35), weight at 49 days (P49), weight gain (G1º, daily weigh gain (GDP) , daily feed consumtion (CDR) feed conversion (CA) , one at 21 days and at 35 days, and two at 35 days and 49 days.

Effects of ZnO and CuSO4 Table 1. 01. , Medias two treatments for weight variations at 21 days (P21) and at 35 dyas (P35), weight gain (GP), daily weigh gain (GPD), daily feed consumption (CDR) feed conversion (CA) at 21 days and 35 days.

Depiction of normal condition in GIT and settle down on mucus layer Treatments P21 P35 GP GPD CDR CA Zinc Oxide 5,171 8.392 3.21 R 0.230 0.303 1.323 AgraZn 250gr5.105 7.935 2.85 0.202 0.288 1.428 AgraZn300gr 5.196 7.800 2.611 0.187 0.255 1.380 MEDIA 5.155 8.142 2.806 0.206 0.282 1.377 CV 16.43 17.19 22.98 23.24 21.49 5.15 Figure 3: Depiction of how glycoproteins in intestinal mucus may intercept pathogenic bacteria (K88 E. coli) thereby preventing attachment to similar glycoproteins of the intestinal (enterocyte) surface. From Mathew, 2001. In normal condition, E. coli are not exerting it’s own toxicity on intestinal surface. Due to some other reason, once mucus layer’s thickness were decreased, the pathogen could exert toxicity on intestinal surface (on epithelial cell). [Mathew. 2001]

AGRAZINC 100 Table 02. Medias for variations in weight at 49 days (P49), weight gain (GP), dialy gain weight (GPD), feed consumption (CDR) , feed conversión (CA) at 35 and 49 days.

AGRAZINC 100 : Effects on E. coli TIME – 35 – 49 days Treatment P49 GP GPD CDR CA A Zn Oxide 13.836 5.445 0.388 0.647 1.667 B AgraZn 250 gr 13.959 6.055 0.432 0.656 1.508 C AgraZn 300 gr 13.709 5.899 0.422 0.632 1.496 MEDIA 13.842 5.799 0.414 0.6430 1.558 CV 15.15 13.41 13.15 15.72 8.45 [Dalian Polytechnic Univ. China, 2007]

AGRAZINC 100 During the trial there was not an ocúrrance of diarreah in the experimental units. Only the 250’ Agrazinc 100 250 gr treatment presented pasty feses, from one day to the other , after the first four days. This same treatment presented hemorrhoids in the first day , but gave a satisfactory response in performance at the end. There was only one death during the trial , as suspicion of encephalitis . An inclusion of 0.5% Tetracid in the first phase caused an inhibition of feed consumption in the first days , a fact that was reified by the attending personnel.

AGRAZINC 100 In the meanwhile , after the first 4 days the feed consumption as noted by the personnel was increasing. At the same time, closed to weighing time, , it was observed some difference in some experimental units in the feed consumption . In graph 1, Basal diet which do not have pharmacological level of ZnO. Basal diet is the control group. If we think control group show normal condition, Test group in intestine show Lactobacilli suppression. Even though, in caecum, free zinc ions are decreased in number, still they exert a suppression effect on E. coli yet. So, it makes promote Lactobacilli’s acitivity.

The limit of ZnO and effects of AGRAZINC 100 An inclusion of 0.5% of Tetracid in the ration with zinc oxide suggests a lesser effect in the inhibition of feed consumption in relation to the rest of the treatments with AGRAZINC 100. The response of AGRAZINC 100 with the two inclusions tested, in the second phase when 0.2% of Tetracid was utilized were 11.2 % and 8.6 %, superior to zinc oxide.

AGRAZINC100 CONCLUSION- There were no difference among the treatments with AGRAZINC 100 of dosages of 250 gr and 300 gr per MT of feed and stancard mineral zinc oxide. Depiction of how non-pathogenic resident bacteria (lactobacilli) may prevent colonization of pathogens (K88 E. coli) on the surface of the gut. Adapted from Mathew, 2001 From this article, we can figure it out how Zn ion perform it’s pharmacological effects on preventing colonization of pathogenic micro organism such as E. coli. According to many published articles related with ZnO’s effects on animal performances, pharmacological level of ZnO prevented excessive proliferation of E. coli in GIT, even beneficial bacteria. However, when we applied AGRAZINC 100 in low inclusion level of Zn ions for this animal at the same stage, we got reduction in E. coli counts but increment in beneficial bacteria. With that in mind, we can say effective free Zinc ions (right on time, even in small amount) prevent E. coli proliferation through blocking the binding sites on intestinal surface, but excessive Zinc ions or Zinc compounds(?) may affect colonization of beneficial bacteria on intestinal surface through blocking it’s binding sites on intestinal surface.

Additional comments from AGRANCO as conclusions of the trial AGRAZINC 100 Additional comments from AGRANCO as conclusions of the trial The added nutritional value by AGRAZINC 100 is adequate for the animals during those stages of the trial. The AGRAZINC 100 DOSAGES are sufficient to controlñ diarreah during those stages of the trial. The effect of AGRAZINC 100 IKN THE INTESTINAL tract is distal and effective during the whole estention of the amall intestine AGRAZINC 100 can be substituted for standard mineral ZNO at a 1 to 12 ratio.

AGRAZINC 100 AGRANCO CORP. USA 2014 S.W. 24 Terrace Miami, Fl. 33145 Tel 305 856 3782 Fax 305 856 3734